Toward RNA interference‐based therapy for filovirus infections
Identifieur interne : 002C70 ( Main/Exploration ); précédent : 002C69; suivant : 002C71Toward RNA interference‐based therapy for filovirus infections
Auteurs : Kevin B. Spurgers [États-Unis] ; Lynn S. Silvestri [États-Unis] ; Kelly L. Warfield [États-Unis] ; Sina Bavari [États-Unis]Source :
- Drug Development Research [ 0272-4391 ] ; 2009-06.
Abstract
Ebola (EBOV) and Marburg (MARV) viruses, of the family filoviridae, cause severe hemorrhagic fever in humans and nonhuman primates (NHPs) with mortality rates of up to 90%. Infection is thought to occur through mucous membranes or breaks in the skin after contact with infected animal tissue or body fluids of infected individuals. Beyond naturally occurring outbreaks, the potential use of these viruses in acts of bioterrorism remains a public health and national security concern. EBOV and MARV are classified as category A bioterrorism agents by the Centers for Disease Control and Prevention (CDC). To date, there are no licensed vaccines or therapeutics for filovirus infections. Major efforts are now under way to develop anti‐viral therapeutics that use the cellular RNA interference (RNAi) pathway. Small synthetic double‐stranded RNA oligonucleotides (siRNAs), or small hairpin RNAs (shRNAs) enter the RNAi pathway and guide the degradation of target mRNA transcripts with homologous sequence, for experimental or therapeutic benefit. Chemical modifications improve the in vivo stability of siRNAs and various strategies are being investigated to improve delivery. Importantly, siRNAs and shRNAs have been successfully used to inhibit virus replication in vitro, and in animal models. siRNAs as therapy for a variety of ailments have now moved into clinical trials. This review provides an overview of therapeutic siRNAs and details preclinical efforts to use these molecules as therapy for filovirus infections. Drug Dev Res 70:246–254, 2009. Published 2009 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/ddr.20302
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001588
- to stream Istex, to step Curation: 001588
- to stream Istex, to step Checkpoint: 000C33
- to stream Main, to step Merge: 002D24
- to stream Main, to step Curation: 002C70
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Toward RNA interference‐based therapy for filovirus infections</title><author><name sortKey="Spurgers, Kevin B" sort="Spurgers, Kevin B" uniqKey="Spurgers K" first="Kevin B." last="Spurgers">Kevin B. Spurgers</name></author><author><name sortKey="Silvestri, Lynn S" sort="Silvestri, Lynn S" uniqKey="Silvestri L" first="Lynn S." last="Silvestri">Lynn S. Silvestri</name></author><author><name sortKey="Warfield, Kelly L" sort="Warfield, Kelly L" uniqKey="Warfield K" first="Kelly L." last="Warfield">Kelly L. Warfield</name></author><author><name sortKey="Bavari, Sina" sort="Bavari, Sina" uniqKey="Bavari S" first="Sina" last="Bavari">Sina Bavari</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8F695DC3706B8D0E196621EAD7C011884B3CAB57</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/ddr.20302</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-KZH1CJ3C-S/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001588</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001588</idno><idno type="wicri:Area/Istex/Curation">001588</idno><idno type="wicri:Area/Istex/Checkpoint">000C33</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C33</idno><idno type="wicri:doubleKey">0272-4391:2009:Spurgers K:toward:rna:interference</idno><idno type="wicri:Area/Main/Merge">002D24</idno><idno type="wicri:Area/Main/Curation">002C70</idno><idno type="wicri:Area/Main/Exploration">002C70</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Toward RNA interference‐based therapy for filovirus infections</title><author><name sortKey="Spurgers, Kevin B" sort="Spurgers, Kevin B" uniqKey="Spurgers K" first="Kevin B." last="Spurgers">Kevin B. Spurgers</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick</wicri:cityArea></affiliation></author><author><name sortKey="Silvestri, Lynn S" sort="Silvestri, Lynn S" uniqKey="Silvestri L" first="Lynn S." last="Silvestri">Lynn S. Silvestri</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick</wicri:cityArea></affiliation></author><author><name sortKey="Warfield, Kelly L" sort="Warfield, Kelly L" uniqKey="Warfield K" first="Kelly L." last="Warfield">Kelly L. Warfield</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick</wicri:cityArea></affiliation></author><author><name sortKey="Bavari, Sina" sort="Bavari, Sina" uniqKey="Bavari S" first="Sina" last="Bavari">Sina Bavari</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick</wicri:cityArea></affiliation><affiliation></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Correspondence address: United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Drug Development Research</title><title level="j" type="sub">Biodefense Countermeasure Development</title><title level="j" type="alt">DRUG DEVELOPMENT RESEARCH</title><idno type="ISSN">0272-4391</idno><idno type="eISSN">1098-2299</idno><imprint><biblScope unit="vol">70</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="246">246</biblScope><biblScope unit="page" to="254">254</biblScope><biblScope unit="page-count">9</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-06">2009-06</date></imprint><idno type="ISSN">0272-4391</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0272-4391</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Ebola (EBOV) and Marburg (MARV) viruses, of the family filoviridae, cause severe hemorrhagic fever in humans and nonhuman primates (NHPs) with mortality rates of up to 90%. Infection is thought to occur through mucous membranes or breaks in the skin after contact with infected animal tissue or body fluids of infected individuals. Beyond naturally occurring outbreaks, the potential use of these viruses in acts of bioterrorism remains a public health and national security concern. EBOV and MARV are classified as category A bioterrorism agents by the Centers for Disease Control and Prevention (CDC). To date, there are no licensed vaccines or therapeutics for filovirus infections. Major efforts are now under way to develop anti‐viral therapeutics that use the cellular RNA interference (RNAi) pathway. Small synthetic double‐stranded RNA oligonucleotides (siRNAs), or small hairpin RNAs (shRNAs) enter the RNAi pathway and guide the degradation of target mRNA transcripts with homologous sequence, for experimental or therapeutic benefit. Chemical modifications improve the in vivo stability of siRNAs and various strategies are being investigated to improve delivery. Importantly, siRNAs and shRNAs have been successfully used to inhibit virus replication in vitro, and in animal models. siRNAs as therapy for a variety of ailments have now moved into clinical trials. This review provides an overview of therapeutic siRNAs and details preclinical efforts to use these molecules as therapy for filovirus infections. Drug Dev Res 70:246–254, 2009. Published 2009 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Spurgers, Kevin B" sort="Spurgers, Kevin B" uniqKey="Spurgers K" first="Kevin B." last="Spurgers">Kevin B. Spurgers</name></region><name sortKey="Bavari, Sina" sort="Bavari, Sina" uniqKey="Bavari S" first="Sina" last="Bavari">Sina Bavari</name><name sortKey="Bavari, Sina" sort="Bavari, Sina" uniqKey="Bavari S" first="Sina" last="Bavari">Sina Bavari</name><name sortKey="Silvestri, Lynn S" sort="Silvestri, Lynn S" uniqKey="Silvestri L" first="Lynn S." last="Silvestri">Lynn S. Silvestri</name><name sortKey="Warfield, Kelly L" sort="Warfield, Kelly L" uniqKey="Warfield K" first="Kelly L." last="Warfield">Kelly L. Warfield</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C70 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C70 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8F695DC3706B8D0E196621EAD7C011884B3CAB57
|texte= Toward RNA interference‐based therapy for filovirus infections
}}
| This area was generated with Dilib version V0.6.33. |  |